New guidance for BMD surveillance in youth post-cancer
An expert panel has evaluated the circumstances demanding surveillance and how it should be conducted
Bone mineral density surveillance of children and young people treated for cancer, if required, should begin two to five years after therapy has ceased, an international panel of experts says.
The new guidelines aim to harmonise advice globally following evaluation of the evidence.
"Some findings - such as the fact that methotrexate was not found to be a risk factor for BMD deficits - may be unexpected for some
